Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported Q1 2025 financial results, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [2] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [2] - The decline in performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [2] Market Reaction - Following the financial results announcement, Globus's stock price dropped by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. following disappointing financial results for Q1 2025, which led to a significant drop in the company's stock price [1][3]. Financial Performance - Globus Medical reported non-GAAP earnings per share of $0.68 for Q1 2025, missing consensus estimates by $0.06 [3]. - The company's revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price decreased by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to several factors, including softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].

Core Viewpoint - Globus Medical, Inc. has authorized a share repurchase program of up to $500 million to address the disconnect between its intrinsic value and market valuation, reflecting confidence in its long-term growth and profitability [1][2]. Group 1: Share Repurchase Program - The share repurchase program is aimed at buying back up to $500 million of the company's outstanding common stock [1]. - The timing and number of shares repurchased will be at management's discretion, influenced by market conditions and other factors [2]. - The program will be funded using the company's cash reserves and aligns with its long-term capital allocation strategy [3]. Group 2: Company Overview - Globus Medical is a leading global musculoskeletal solutions company focused on addressing unmet clinical needs and improving patient outcomes [4]. - The company emphasizes innovation, education, and clinical support across various areas including spine, orthopedic trauma, and joint reconstruction [4].

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq. Admitted CA, NY and TX Bars lesley@portnoylaw.com 310-692-8883 www.portnoylaw.com Attorney Advertising On May 8, 2025, Globus issued a press release announcing its financial results for the first quarter of 2025. The Company reported non-G ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. following disappointing financial results for Q1 2025, which led to a significant drop in the company's stock price [1][3]. Financial Performance - Globus Medical reported non-GAAP earnings per share of $0.68 for Q1 2025, missing consensus estimates by $0.06 [3]. - The company's revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price decreased by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Investigation Details - The investigation by Pomerantz LLP is aimed at determining whether Globus and its officers or directors engaged in any fraudulent activities related to securities [1].

Globus Medical, Inc. (GMED) reported first-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which missed the Zacks Consensus Estimate by 8.1%. The figure increased 7.9% year over year. Net sales generated in the United States increased 0.2% year over year (same at CER) to $483.9 million, which missed our model's projection of $519.2 million. Across international markets, revenues decreased 7.7% (down 4.6% at CER) to $114.3 million, which also missed our model estimate of $124.6 million. GMED's Pr ...

Core Viewpoint - Globus Medical reported a decline in net sales for Q1 2025, attributed to multiple factors including slowed technology transactions, supply chain disruptions, and fluctuations in international distributor orders, although the core U.S. spine business performed well [4][6]. Financial Performance - For Q1 2025, Globus Medical's global net sales were $598.1 million (approximately 4.3 billion RMB), a year-over-year decrease of 1.4%. On a constant currency basis, the decline was 0.8% [6]. - The GAAP net income for the quarter was $75.5 million, with a GAAP diluted earnings per share (EPS) of $0.54 and a non-GAAP diluted EPS of $0.68 [6]. - The company generated a record free cash flow of $141.2 million during the quarter and reaffirmed its full-year revenue guidance of $2.8 to $2.9 billion, while updating its non-GAAP EPS guidance to a range of $3.00 to $3.30 [6]. Mergers and Acquisitions - In February 2023, Globus Medical announced a $3.1 billion (approximately 21.1 billion RMB) acquisition of NuVasive, with NuVasive shareholders owning about 28% of the combined company post-transaction [4][7]. - The acquisition of Nevro for approximately $250 million was announced in early 2025, with a premium of 27% over Nevro's average stock price over the past 90 days [9][11]. Strategic Developments - The merger with NuVasive is expected to enhance the combined company's capabilities in the $50 billion global market for spine and orthopedic technologies, with analysts praising the integration as one of the most successful in the spine industry [7]. - The company launched 18 new products in 2024, including innovations that leverage the strengths of both companies, such as the ExcelsiusHub robotic platform integrated with Pulse neuro-monitoring technology [13]. Leadership Changes - In February 2025, the company announced that President Anthony L. Williams would leave by May 31, 2025, with CEO Dan Scavilla temporarily taking over the role to ensure operational stability during the transition [8].

Core Viewpoint - Globus Medical reported a decline in revenue and earnings for the quarter ended March 2025, missing Wall Street expectations, indicating potential challenges in financial performance [1][2]. Financial Performance - Revenue for the quarter was $598.12 million, down 1.4% year-over-year, and below the Zacks Consensus Estimate of $628.32 million by 4.81% [1]. - Earnings per share (EPS) were $0.68, a decrease from $0.72 in the same quarter last year, and fell short of the consensus estimate of $0.74 by 8.11% [1]. Geographic Revenue Breakdown - International revenue was reported at $114.26 million, which is 7.7% lower than the three-analyst average estimate of $127.52 million [4]. - U.S. revenue stood at $483.86 million, slightly up by 0.2% year-over-year, but below the average estimate of $510.72 million [4]. Product Category Performance - Net sales from Enabling Technologies were $22.19 million, significantly lower than the estimated $38.79 million, reflecting a year-over-year decline of 30.6% [4]. - Musculoskeletal Solutions generated $575.93 million in sales, which was marginally above the year-ago figure by 0.2%, but still below the estimated $598.85 million [4]. Stock Performance - Shares of Globus Medical have returned -3.7% over the past month, contrasting with the Zacks S&P 500 composite's increase of 11.3% [3]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3].

Core Viewpoint - Globus Medical reported quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.74 per share, and showing a decline from $0.72 per share a year ago, indicating an earnings surprise of -8.11% [1][2] Financial Performance - The company posted revenues of $598.12 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 4.81%, and down from $606.67 million year-over-year [2] - Over the last four quarters, Globus Medical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - Globus Medical shares have declined approximately 13.5% since the beginning of the year, compared to a decline of -4.3% for the S&P 500 [3] - The current Zacks Rank for Globus Medical is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.86 on revenues of $671.54 million, and for the current fiscal year, it is $3.45 on revenues of $2.68 billion [7] - The estimate revisions trend for Globus Medical is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - The Medical - Instruments industry, to which Globus Medical belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Data and Key Metrics Changes - Revenue for Q1 was $598 million, reflecting a slight decline of 0.8% year-over-year on a constant currency basis [7][21] - Non-GAAP EPS increased by 9% to $0.68 compared to the prior year [8][22] - Free cash flow reached a record $141 million, up 493% year-over-year [9][36] - GAAP net income was $75.5 million, translating to fully diluted GAAP earnings of $0.54 per share [22] Business Line Data and Key Metrics Changes - U.S. Spine revenue grew by 2% in Q1, driven by strong product portfolio performance [10][23] - Enabling Technologies revenue decreased by 31% to $22 million, impacted by market uncertainty [14][21] - International Spine implant business grew by 1% on a constant currency basis, affected by distributor order timing [15][29] - Combined trauma and NSO business declined by 8%, although core trauma grew by 34% [16] Market Data and Key Metrics Changes - U.S. Spine business showed above-market growth exiting April, with positive momentum expected in Q2 [11][12] - International revenue was $114.3 million, down 7.7% as reported, primarily due to supply chain disruptions [29] - The overall market for musculoskeletal products is expected to recover as supply chain issues are resolved [36] Company Strategy and Development Direction - The company aims to focus on sustained profitable growth and operational excellence while integrating the Nevro acquisition [10][18] - The acquisition of Nevro is seen as a strategic move to expand into the musculoskeletal market, adding a $3 billion market space [16][17] - The company plans to leverage its financial strength to accelerate investments in neuromodulation and improve cash flow [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering from Q1 challenges, citing improvements in U.S. Spine and supply chain remediation [46][48] - The company anticipates a strong Q2 performance, with positive trends in sales and order fulfillment [40][41] - Management acknowledged the impact of market uncertainty but remains optimistic about long-term growth potential [76][78] Other Important Information - The company returned to debt-free status after paying off nearly $900 million in debt from the NuVasive merger [9][33] - The company has completed its share repurchase program, buying back over 20% of the dilution from the merger [34][35] - The company is actively addressing tariff impacts through cost action offsets and vendor negotiations [38][116] Q&A Session Summary Question: Confidence in recovery from Q1 performance - Management noted that supply chain disruptions and timing of distributor orders were temporary issues, with confidence in a recovery in Q2 [46][48] Question: Synergies from Nevro acquisition - Focus will be on reducing operational expenses and improving gross margins over time [50][51] Question: Impact of competitors on sales cycles - No significant impact from competitors was noted, although financing options are being explored [56] Question: Organic growth guidance - Organic growth components remain consistent, with expectations to recover lost sales from Q1 [72][82] Question: FDA warning letter status - Progress has been made, and management is awaiting inspection to resolve the issue [98] Question: Future M&A plans - Near-term focus will be on integrating Nevro and NuVasive before pursuing further acquisitions [99] Question: Market growth and procedural health - Management indicated some slowdown in market growth but emphasized the importance of clearing back orders and launching new products [101][102]